VNDA - Vanda Pharmaceuticals Inc.
NEXT EARNINGS:
May 6, 2026
EPS Est: $-0.24
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.17
DETAILS
HIGH:
$24.00
LOW:
$7.50
MEDIAN:
$11.00
CONSENSUS:
$14.17
UPSIDE:
73.44%
Market Cap:
482.91M
Volume:
7,495,305
Avg Volume:
1,786,236
52 Week Range:
3.81-9.6
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.58
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
368
IPO Date:
2006-04-12
EPS (TTM):
-3.74
P/E Ratio:
-2.36
Revenue (TTM):
216.10M
Total Assets:
488.95M
Total Debt:
12.62M
Cash & Equiv:
84.85M
Rev Growth (5Y):
-2.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-44.0%
Debt/Equity:
0.04
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-11 | $-2.39 | $-2.18 | -9.6% | $57.2M | $61.8M | -7.4% |
| 2025-10-29 | $-0.38 | $-0.31 | -22.6% | $56.3M | $59.3M | -5.1% |
| 2025-07-31 | $-0.46 | $-0.34 | -35.3% | $52.6M | $58.7M | -10.5% |
| 2025-05-07 | $-0.50 | $-0.55 | +9.1% | $50.0M | $45.1M | +10.9% |
| 2025-02-13 | $-0.08 | $-0.14 | +42.9% | $53.2M | $52.2M | +1.8% |
| 2024-11-06 | $-0.09 | $-0.17 | +47.1% | $47.7M | $49.1M | -3.0% |
| 2024-07-31 | $-0.08 | $-0.21 | +61.9% | $50.5M | $50.7M | -0.5% |
| 2024-05-08 | $-0.07 | $0.05 | -240.0% | $47.5M | $48.5M | -2.1% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.10M | 198.77M | 192.64M | 254.38M | 268.68M | 248.17M | 227.19M | 193.12M | 165.08M | 146.02M | 109.92M | 50.16M |
| Net Income | (220.47M) | (18.90M) | 2.51M | 6.28M | 33.15M | 23.34M | 115.55M | 25.21M | (15.57M) | (18.01M) | (39.87M) | 20.19M |
| EPS | -3.74 | -0.32 | 0.04 | 0.11 | 0.60 | 0.43 | 2.17 | 0.50 | -0.35 | -0.41 | -0.94 | 0.58 |
| Total Assets | 488.95M | 656.20M | 648.44M | 634.25M | 593.79M | 533.46M | 483.75M | 332.13M | 205.43M | 210.37M | 213.05M | 171.70M |
| Total Debt | 12.62M | 12.36M | 9.40M | 11.14M | 12.37M | 13.61M | 14.60M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 84.85M | 102.32M | 135.82M | 135.03M | 52.07M | 61.03M | 45.07M | 61.01M | 33.63M | 40.43M | 50.84M | 60.90M |
| Operating Cash Flow | (109.44M) | (15.76M) | 12.80M | 31.98M | 64.21M | 51.77M | 45.95M | 29.99M | (1.98M) | (8.10M) | 12.45M | (81.55M) |
| Free Cash Flow | (110.44M) | (16.25M) | 12.42M | 31.30M | 63.66M | 49.98M | 44.93M | 4.62M | (3.65M) | (9.51M) | 9.92M | (90.32M) |
| FCF per Share | -1.87 | -0.28 | 0.22 | 0.55 | 1.15 | 0.92 | 0.85 | 0.09 | -0.08 | -0.22 | 0.23 | -2.60 |
| Book Value | 327.19M | 538.55M | 544.91M | 527.20M | 504.93M | 453.27M | 410.94M | 275.42M | 131.39M | 131.33M | 133.03M | 160.82M |
| Cash & ST Investments | 263.85M | 374.64M | 388.26M | 466.86M | 432.81M | 367.74M | 312.13M | 257.36M | 143.41M | 141.34M | 143.18M | 129.82M |
| ROC Equity | -0.67 | -0.04 | 0.00 | 0.01 | 0.07 | 0.05 | 0.28 | 0.09 | -0.12 | -0.14 | -0.30 | 0.13 |